A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Feb 2019
At a glance
- Drugs Tralokinumab (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms ECZTRA 2
- Sponsors LEO Pharma
- 16 Jul 2018 Planned End Date changed from 6 Nov 2019 to 1 Aug 2019.
- 16 Jul 2018 Planned primary completion date changed from 6 Nov 2019 to 1 Sep 2018.
- 17 Apr 2018 Status changed from recruiting to active, no longer recruiting.